2.65
-0.07(-2.57%)
Currency In USD
| Previous Close | 2.72 |
| Open | 2.72 |
| Day High | 2.75 |
| Day Low | 2.64 |
| 52-Week High | 3.2 |
| 52-Week Low | 1.26 |
| Volume | 181,084 |
| Average Volume | 275,151 |
| Market Cap | 73.87M |
| PE | -3.84 |
| EPS | -0.69 |
| Moving Average 50 Days | 2.47 |
| Moving Average 200 Days | 2.02 |
| Change | -0.07 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $722.07 as of August 02, 2025 at a share price of $2.65. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $1,055.78 as of August 02, 2025 at a share price of $2.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
GlobeNewswire Inc.
Jul 11, 2025 1:36 PM GMT
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Jul 07, 2025 1:35 PM GMT
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA,
Immix Biopharma Attends FDA CEO Forum in Washington DC
GlobeNewswire Inc.
Jun 06, 2025 1:39 PM GMT
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopha